Ultragenyx Pharmaceutical (RARE) Total Current Liabilities (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Total Current Liabilities of $325.0 million for Q1 2026, up 11.43% year-over-year from $291.7 million in Q1 2025, and down 15.36% quarter-over-quarter from $384.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Total Current Liabilities (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Total Current Liabilities for 14 consecutive years, with $325.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 11.43% year-over-year to $325.0 million; the TTM figure through Mar 2026 stood at $325.0 million (up 11.43% YoY), while the FY2025 annual figure was $384.0 million, up 11.63% from the prior year.
- Total Current Liabilities slipped to $325.0 million in Q1 2026 per RARE's latest filing, from $384.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $384.0 million in Q4 2025 and bottomed at $167.2 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $273.8 million across 5 years, with a median of $272.9 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 73.64% — and 2023, when it increased 7.36%.
- Ultragenyx Pharmaceutical's Total Current Liabilities stood at $261.2 million in 2022, then advanced by 7.36% to $280.4 million in 2023, then increased by 22.67% to $344.0 million in 2024, then rose by 11.63% to $384.0 million in 2025, then fell by 15.36% to $325.0 million in 2026.
- Business Quant data shows RARE's Total Current Liabilities at $325.0 million in Q1 2026, $384.0 million in Q4 2025, and $340.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 351.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 351.00 Mn |
| Mar 31, 2026 | 325.00 Mn |
| Dec 31, 2025 | 384.00 Mn |
| Sep 30, 2025 | 340.02 Mn |
| Jun 30, 2025 | 293.24 Mn |
| Mar 31, 2025 | 291.67 Mn |
| Dec 31, 2024 | 344.00 Mn |
| Sep 30, 2024 | 285.01 Mn |
| Jun 30, 2024 | 272.87 Mn |
| Mar 31, 2024 | 245.58 Mn |
| Dec 31, 2023 | 280.44 Mn |
| Sep 30, 2023 | 253.98 Mn |
| Jun 30, 2023 | 244.38 Mn |
| Mar 31, 2023 | 218.18 Mn |
| Dec 31, 2022 | 261.21 Mn |
| Sep 30, 2022 | 227.36 Mn |
| Jun 30, 2022 | 220.64 Mn |
| Mar 31, 2022 | 167.23 Mn |
| Dec 31, 2021 | 181.37 Mn |
| Sep 30, 2021 | 135.93 Mn |